Allakos INC. Stock Price Prediction

ALLK – Allakos INC. Stock Price Prediction 2023-2025-2030

Introduction:

If you are trying to learn about Allakos INC. Stock Price Prediction, you will get it all here. Along with the predictions, you also get the proper information on this stock so that you can make a good investment decision for your portfolio. To make these predictions, we have used advanced AI tools along with CAGR techniques and have gone through many reliable resources. Go through the article below to get what you have been seeking for.

About Allakos Stock (NASDAQ:ALLK)

Allakos Inc. (NASDAQ : ALLK) is a biopharmaceutical company that develops innovative therapeutic antibodies to treat various allergic and inflammatory diseases. The company is headquartered in California, USA, and was founded in 2012.

Allakos focuses on the development of antibodies that target the underlying biological mechanisms of various diseases, including eosinophilic gastritis, chronic urticaria, and atopic dermatitis. The company’s lead product candidate, AK002, is currently being evaluated in clinical trials for the treatment of several conditions, including eosinophilic gastritis and eosinophilic esophagitis.

Allakos went public in 2018 and is listed on the NASDAQ stock exchange. As with all publicly traded companies, the price of Allakos stock can be influenced by a variety of factors, including the performance of its clinical trials, regulatory decisions, and broader market trends.

What Is Allakos Stock?

Allakos Inc. (NASDAQ:ALLK) is a publicly traded company listed on the NASDAQ stock exchange. As of my knowledge cutoff in September 2021, the company had a market capitalization of around $4 billion and a share price of around $105.

Like all biopharmaceutical companies, Allakos’ stock price can be influenced by a variety of factors, including the performance of its clinical trials, regulatory decisions, and broader market trends. The company’s clinical trial results and regulatory updates are closely watched by investors, as they can have a significant impact on the company’s future prospects and stock price.

Allakos has several ongoing clinical trials evaluating the safety and efficacy of its lead product candidate, AK002, for the treatment of various allergic and inflammatory diseases. The company has reported positive results from some of these trials, which has helped to boost investor confidence in the company’s potential.

However, as with any investment, there are risks associated with investing in Allakos stock. Biopharmaceutical companies are highly dependent on the success of their clinical trials, and there is no guarantee that Allakos’ clinical trials will be successful or that its products will receive regulatory approval. Additionally, the biopharmaceutical industry is highly competitive, and Allakos faces competition from other companies developing similar treatments for allergic and inflammatory diseases. It’s important to conduct thorough research and consult with a financial advisor before making any investment decisions.

Allakos Stock Current Price(NASDAQ:ALLK)

Video

Graph On ALLK-Allakos Stock Price Prediction 

Price Graph

Price Change Graph

ALLK-Allakos Stock Price Prediction 

Five analysts have provided price targets for Allakos Inc for the next 12 months, with a median target of 7.00 and ranges from 9.00 to 4.00. From the previous price of 5.93, the median estimate is up 18.14%.

According to consensus expert opinion, the average price target for Allakos for the next year is $8.00. The consensus estimate for Allakos’s future growth in share price is 30.51%. The top-performing stocks that have been consistently rated by analysts as either a “Strong Buy” or “Strong Sell” may be found in the Analysts’ Top Stocks feature.

The consensus target price for Allakos Inc among the 7 analysts providing projections for the next 12 months is 7.00, with the range going from 9.00 to 4.00. Compared to the previous price of $6.12, the median estimate is a price increase of 14.38 percent.

ALLK-Allakos Stock Prediction – 2023- 2025-2030

YearMinimum PriceAverage PriceMaximum Price
2023$3.02$5.72$8.42
2024$4.53$8.58$12.6
2025$6.79$12.87$18.9
2026$10.1$19.2$28.3
2027$15.15$28.8$42.4
2028$22.7$43.2$63.6
2029$34.05$64.8$95.4
2030$51.07$97.2$143
Table on Allakos Stock Price Prediction

All the above-given Allakos Stock price prediction forecasts use real-time Allakos Stock market data and all data is updated live on our website. This allows us to provide dynamic price predictions based on current market activity.

Allakos Stock Price Prediction For Every Upcoming Year

For 2023:

The sum of all 4098 projections is 2366.52%. We have 9 monthly forecasts for Allakos stock in 2023, with an average prognosis of $5.72, a high prediction of $8.42, and a low estimate of $3.02. Stocks are expected to rise by 50% percent in 2023, according to the average projection for Allakos.

For 2024:

There are 12 monthly forecasts made for Allakos stock in 2024, with an average prognosis of $8.58, a high prediction of $12.6, and a low prediction of $4.53. The average Allakos stock projection for 2023 projects a gain of 45% from 2023.

For 2025:

There are 12 forecasts made for each month in 2025 about the price of Allakos stock, with an average prognosis of $12.87, a high forecast of $18.9, and a low forecast of $6.79. The average Allakos stock prediction for 2025 is a rise of 52% from 2024.

For 2026:

There are 12 forecasts total, one for each month of 2026, for the price of Allakos stock. The average forecast is $19.2, the high estimate is $28.3, and the low forecast is $10.1. The average Allakos stock price prediction for 2026 estimates the stock will rise in value by 50% from 2025.

For 2027:

There are a total of 12 forecasts for Allakos stock in 2027, one for each month of the year. The average prognosis is $28.8, the high estimate is $42.4, and the low forecast is $15.15. From its current price of $4.66, the average Allakos stock projection for 2027 estimates a price gain of 55% from 2026.

For 2028:

There are three forecasts made for each month of 2028 about the price of Allakos stock: an average prognosis of $43.2, a high prediction of $63.6, and a low prediction of $17.94. By looking at the average Allakos stock projection for 2028, we see a price gain of 48% from the last year.

For 2029:

The forecast made for Allakos stock in 2029 has an average stock price of $64.8, a high prediction of $95.4, and a low prediction of $34.05. By looking at the price of stock in 2029, we see a price gain of around 50% from the last year.

For 2030:

The forecast made for Allakos stock in 2030 has an average stock price of $97.2, a high prediction of $143, and a low prediction of $51.07. By looking at the price of stock in 2030, we see a price gain of around 48% from the last year.

ALLK-Allakos Stock Technical Analysis

The purpose of technical analysis is to find trends and patterns in stock price and volume using charts and other analytical techniques. Technical analysts have faith that stock price and volume data from the past may provide insight into the present and future of the market.

These reports are exclusive to members. See the sample video to get an idea of the report’s format, then join up right away to get started.

There is NO COST associated with signing up. An unpaid ChartMill account will never be upgraded without the user’s explicit consent.

Stock in Allakos, which is currently selling for $4.66 on a volume of 72,981, may be causing institutional investors to cause concern due to its precipitous decrease over the past several months. In February, the company’s board and management failed to position the firm’s money supply to take advantage of market volatility by providing additional value to investors.

Stocks like Allakos’s can help shield portfolios from the effects of market volatility, but only if they are part of a diversified portfolio. The current 90-day investment horizon stock returns standard deviation is 3.55 standard deviations. The approaching earnings calls from Allakos’s partners, as well as the general unpredictability of the market, are the primary sources of this higher-than-usual degree of risk.

ALLK-Allakos Stock Fundamental Analysis

Allakos Inc. is a clinical-stage biotechnology company focused on developing novel antibody-based therapeutics for the treatment of various allergic and inflammatory diseases. The company is headquartered in California, USA.

Revenue: Allakos Inc. reported total revenue of $0.25 million in the third quarter of 2021, compared to $0.12 million in the same period last year. The company is not yet profitable and has been reporting net losses every quarter.

Profitability: Allakos Inc. has not yet reported a net profit since its inception. The company has been investing heavily in research and development to advance its drug candidates through clinical trials.

Valuation: Allakos Inc.’s market capitalization as of March 1, 2023, was approximately $3.25 billion, with a price-to-sales ratio of 147.55. The company’s price-to-book ratio is 9.73, and its price-to-earnings ratio is not available as the company is not yet profitable.

Financial Health: Allakos Inc. had cash and cash equivalents of $767.4 million as of September 30, 2021. The company has been relying on equity financing to fund its operations and has not reported any long-term debt.

Clinical Trials: Allakos is currently conducting Phase 3 clinical trials for its lead drug candidate, AK002, for the treatment of eosinophilic gastritis and eosinophilic duodenitis. The company has also completed Phase 2 clinical trials for the treatment of various other allergic and inflammatory diseases.

Overall, Allakos is a clinical-stage biotechnology company that has been investing heavily in research and development to advance its drug candidates through clinical trials. The company has not yet reported a net profit and has been relying on equity financing to fund its operations. Investors should consider the risks associated with investing in a clinical-stage biotech company and conduct their own due diligence before making any investment decisions.

Some Related Posts:-

Conclusion:-

So, that’s all about the Allakos Stock Prediction – 2023, 2025, 2030. Investors should conduct their own research and analysis before making any investment decisions. It’s important to consider the risks associated with investing in a clinical-stage biotech company, such as the potential for setbacks in clinical trials and the need for continued funding to support ongoing research and development. Additionally, market conditions and industry trends can impact the performance of a stock. Therefore, investors should consider their investment goals, risk tolerance, and the overall market conditions before making any investment decisions related to Allakos stock.

Ultimately, the decision to invest in a particular stock, including Volt, should be based on careful consideration of all available information and your own personal financial situation and goals.

FAQs (Frequently Asked Questions)

Q1. Is Allakos a public company?

Ans:- Biotech Allakos Inc. priced its initial public offering at $18 a share, above its $15 to $17 price range.

Q2. What kind of company is Volt?

Ans:- One of the most common methods of setting a target price is achieved by first identifying a technical chart pattern. After the pattern is identified, price targets can be set by measuring the height of the pattern and then adding it to (or subtracting it from) the breakout price.One analyst out of four (25%) recommends a Strong Buy in ALLK, while none (0%) recommends a Buy, two (50%) suggest a Hold, none (0%) recommend a Sell, and one (25%) recommends a Strong Sell. Here’s how to acquire Allakos stock if you’re just starting out in the stock market.

Q3. How do you predict the target price of a stock?

Ans:- One of the most common methods of setting a target price is achieved by first identifying a technical chart pattern. After the pattern is identified, price targets can be set by measuring the height of the pattern and then adding it to (or subtracting it from) the breakout price.

Important Note :- Please note that the predictions presented in this article regarding Allakos INC.(ALLK) stock market performance are based on analysis conducted by reputable sources and industry experts. These predictions are derived from a combination of extensive research and the utilization of techniques such as Compound Annual Growth Rate (CAGR). While these predictions provide valuable insights, it’s important to remember that the stock market is inherently unpredictable, and actual results may vary. Investors should exercise caution and conduct their own due diligence before making any investment decisions.

Leave a Comment

Your email address will not be published. Required fields are marked *

Scroll to Top